BiomX target adjusted to $21 from $2 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on BiomX (PHGE) to $21 from $2 and keeps a Buy rating on the shares. The new target reflects the company’s 1-for-10 reverse-split in August 2024. BiomX also announced positive results from its Phase 2 trial of BX211 for diabetic foot osteomyelitis associated with S. aureus, the analyst tells investors in a research note.